These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

118 related items for PubMed ID: 32689602

  • 1. Dabigatran-induced chronic progressive immune hemolytic anemia: A case report.
    Gong JH, Liu GJ, Zhou F, Sun ZQ.
    J Stroke Cerebrovasc Dis; 2020 Aug; 29(8):104924. PubMed ID: 32689602
    [Abstract] [Full Text] [Related]

  • 2. Acute Kidney Injury in Asians With Atrial Fibrillation Treated With Dabigatran or Warfarin.
    Chan YH, Yeh YH, See LC, Wang CL, Chang SH, Lee HF, Wu LS, Tu HT, Kuo CT.
    J Am Coll Cardiol; 2016 Nov 29; 68(21):2272-2283. PubMed ID: 27884245
    [Abstract] [Full Text] [Related]

  • 3. Locations and Mucosal Lesions Responsible for Major Gastrointestinal Bleeding in Patients on Warfarin or Dabigatran.
    Kolb JM, Flack KF, Chatterjee-Murphy P, Desai J, Wallentin LC, Ezekowitz M, Connolly S, Reilly P, Brueckmann M, Ilgenfritz J, Aisenberg J.
    Dig Dis Sci; 2018 Jul 29; 63(7):1878-1889. PubMed ID: 29582237
    [Abstract] [Full Text] [Related]

  • 4. Individual Treatment Effect Estimation of 2 Doses of Dabigatran on Stroke and Major Bleeding in Atrial Fibrillation.
    Stam-Slob MC, Connolly SJ, van der Graaf Y, van der Leeuw J, Dorresteijn JAN, Eikelboom JW, Peters RJG, Alings M, Visseren FLJ.
    Circulation; 2019 Jun 18; 139(25):2846-2856. PubMed ID: 31046423
    [Abstract] [Full Text] [Related]

  • 5. Dabigatran vs. warfarin in relation to the presence of left ventricular hypertrophy in patients with atrial fibrillation- the Randomized Evaluation of Long-term anticoagulation therapY (RE-LY) study.
    Verdecchia P, Reboldi G, Angeli F, Mazzotta G, Lip GYH, Brueckmann M, Kleine E, Wallentin L, Ezekowitz MD, Yusuf S, Connolly SJ, Di Pasquale G.
    Europace; 2018 Feb 01; 20(2):253-262. PubMed ID: 28520924
    [Abstract] [Full Text] [Related]

  • 6. Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation.
    Yao X, Abraham NS, Sangaralingham LR, Bellolio MF, McBane RD, Shah ND, Noseworthy PA.
    J Am Heart Assoc; 2016 Jun 13; 5(6):. PubMed ID: 27412905
    [Abstract] [Full Text] [Related]

  • 7. Renal Function and Outcomes With Dabigatran Dual Antithrombotic Therapy in Atrial Fibrillation Patients After PCI.
    Hohnloser SH, Steg PG, Oldgren J, Nickenig G, Kiss RG, Ongen Z, Navarro Estrada JL, Oude Ophuis T, Lip GYH, Nordaby M, Kleine E, Ten Berg JM, Bhatt DL, Cannon CP, RE-DUAL PCI Steering Committee and Investigators.
    JACC Cardiovasc Interv; 2019 Aug 26; 12(16):1553-1561. PubMed ID: 31439336
    [Abstract] [Full Text] [Related]

  • 8. Safety and effectiveness of non-vitamin K oral anticoagulants versus warfarin in real-world patients with non-valvular atrial fibrillation: a retrospective analysis of contemporary Japanese administrative claims data.
    Kohsaka S, Katada J, Saito K, Jenkins A, Li B, Mardekian J, Terayama Y.
    Open Heart; 2020 Aug 26; 7(1):e001232. PubMed ID: 32341789
    [Abstract] [Full Text] [Related]

  • 9. Oral anticoagulants usage in Japanese patients aged 18-74 years with non-valvular atrial fibrillation: a retrospective analysis based on insurance claims data.
    Ohshima A, Koyama T, Ogawa A, Zamami Y, Tanaka HY, Kitamura Y, Sendo T, Hinotsu S, Miller MW, Kano MR.
    Fam Pract; 2019 Nov 18; 36(6):685-692. PubMed ID: 31329899
    [Abstract] [Full Text] [Related]

  • 10. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack.
    Coleman CI, Peacock WF, Bunz TJ, Alberts MJ.
    Stroke; 2017 Aug 18; 48(8):2142-2149. PubMed ID: 28655814
    [Abstract] [Full Text] [Related]

  • 11. Dabigatran in nonvalvular atrial fibrillation: from clinical trials to real-life experience.
    Mumoli N, Mastroiacovo D, Tamborini-Permunian E, Vitale J, Giorgi-Pierfranceschi M, Cei M, Dentali F.
    J Cardiovasc Med (Hagerstown); 2017 Jul 18; 18(7):467-477. PubMed ID: 28509761
    [Abstract] [Full Text] [Related]

  • 12. Dabigatran use in elderly patients with atrial fibrillation.
    Avgil-Tsadok M, Jackevicius CA, Essebag V, Eisenberg MJ, Rahme E, Behlouli H, Pilote L.
    Thromb Haemost; 2016 Jan 18; 115(1):152-60. PubMed ID: 26354766
    [Abstract] [Full Text] [Related]

  • 13. Pharmacokinetics/Pharmacodynamics of Dabigatran 75 mg Twice Daily in Patients With Nonvalvular Atrial Fibrillation and Severely Impaired Renal Function.
    Martin JL, Esmaeili H, Manuel RC, Petrini M, Wiebe S, Maas H.
    J Cardiovasc Pharmacol Ther; 2018 Sep 18; 23(5):399-406. PubMed ID: 29695165
    [Abstract] [Full Text] [Related]

  • 14. Dabigatran Versus Warfarin After Bioprosthesis Valve Replacement for the Management of Atrial Fibrillation Postoperatively: DAWA Pilot Study.
    Durães AR, de Souza Roriz P, de Almeida Nunes B, Albuquerque FP, de Bulhões FV, de Souza Fernandes AM, Aras R.
    Drugs R D; 2016 Jun 18; 16(2):149-54. PubMed ID: 26892845
    [Abstract] [Full Text] [Related]

  • 15. Dabigatran must be used carefully: literature review and recommendations for management of adverse events.
    Lin S, Wang Y, Zhang L, Guan W.
    Drug Des Devel Ther; 2019 Jun 18; 13():1527-1533. PubMed ID: 31190734
    [Abstract] [Full Text] [Related]

  • 16. Comparative safety and effectiveness of dabigatran vs. rivaroxaban and apixaban in patients with non-valvular atrial fibrillation: a retrospective study from a large healthcare system.
    Villines TC, Ahmad A, Petrini M, Tang W, Evans A, Rush T, Thompson D, Oh K, Schwartzman E.
    Eur Heart J Cardiovasc Pharmacother; 2019 Apr 01; 5(2):80-90. PubMed ID: 30500885
    [Abstract] [Full Text] [Related]

  • 17. Dabigatran Etexilate: A Review in Nonvalvular Atrial Fibrillation.
    Blair HA, Keating GM.
    Drugs; 2017 Mar 01; 77(3):331-344. PubMed ID: 28185082
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Asians With Nonvalvular Atrial Fibrillation.
    Chan YH, See LC, Tu HT, Yeh YH, Chang SH, Wu LS, Lee HF, Wang CL, Kuo CF, Kuo CT.
    J Am Heart Assoc; 2018 Apr 05; 7(8):. PubMed ID: 29622587
    [Abstract] [Full Text] [Related]

  • 19. A Review of and Recommendations for the Management of Patients With Life-Threatening Dabigatran-Associated Hemorrhage: A Single-Center University Hospital Experience.
    Kumar R, Smith RE, Henry BL.
    J Intensive Care Med; 2015 Dec 05; 30(8):462-72. PubMed ID: 24668159
    [Abstract] [Full Text] [Related]

  • 20. Dabigatran affects thrombin-dependent platelet aggregation after a week-long therapy.
    Sokol J, Nehaj F, Ivankova J, Mokan M, Mokan M, Stasko J.
    Scand Cardiovasc J; 2018 Aug 05; 52(4):227-231. PubMed ID: 29842807
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.